Skip to main content
Year archive

Sinco Pharmaceuticals Holdings Limited — 2024 filings

All 150 regulatory filings released by Sinco Pharmaceuticals Holdings Limited (6833) in 2024, sourced directly from the official regulator.

150 Filings
2024 Period
2024 filings (150)
Filing Released Lang
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS FROM PHASE III STUDY OF BENMELSTOBART INJECTION IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY SEQUENTIAL COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES VERS
Regulatory Filings
2024-12-26 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information
2024-12-24 English
APPOINTMENT OF VICE CHAIRMAN OF THE BOARD AND NON-EXECUTIVE DIRECTOR
Board/Management Information
2024-12-24 English
VOLUNTARY ANNOUNCEMENT - PERMISSION OBTAINED TO SUBMIT MARKETING APPLICATION FOR THE INDICATION OF BENMELSTOBART INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES FOR TREATMENT OF ADVANCE
Regulatory Filings
2024-12-19 English
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS FROM PHASE III STUDY OF BENMELSTOBART INJECTION WITH OR WITHOUT ANLOTINIB HYDROCHLORIDE CAPSULES AS CONSOLIDATION THERAPY AFTER CHEMORADIOTHERAPY FOR NON-SMAL
Regulatory Filings
2024-12-18 English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF "ERIBULIN MESILATE INJECTION"
Regulatory Filings
2024-12-11 English
VOLUNTARY ANNOUNCEMENT - ENTERING INTO GLOBAL COLLABORATION AGREEMENT WITH BIOSION AND ACLARIS THERAPEUTICS
Regulatory Filings
2024-12-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
Regulatory Filings
2024-12-03 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2024
Regulatory Filings
2024-12-02 English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF BENMELSTOBART INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULE FOR THE INDICATION OF TREATMENT FOR ENDOMETRIAL CANCER
Regulatory Filings
2024-11-27 English
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW INDICATION APPLICATION FOR MARKETING OF ANLOTINIB HYDROCHLORIDE CAPSULE IN COMBINATION WITH PENPULIMAB INJECTION FOR FIRST-LINE TREATMENT OF ADVANCED HEPATOC
Regulatory Filings
2024-11-21 English
VOLUNTARY ANNOUNCEMENT - SIGNING EQUITY INVESTMENT AND STRATEGIC COOPERATION AGREEMENT WITH LANOVA MEDICINES
Capital/Financing Update
2024-11-19 English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ACQUISITION OF 29.99% EQUITY INTEREST IN THE TARGET COMPANY
Capital/Financing Update
2024-11-17 English
VOLUNTARY ANNOUNCEMENT - APPROVAL GRANTED FOR CLINICAL TRIALS OF THE FOURTH-GENERATION EGFR INHIBITOR "TQB3002" IN THE UNITED STATES
Regulatory Filings
2024-11-14 English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF KRAS G12C INHIBITOR "GARSORASIB" TABLET
Regulatory Filings
2024-11-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
Regulatory Filings
2024-11-04 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2024
Regulatory Filings
2024-11-01 English
VOLUNTARY DISCLOSURE - 2024 THIRD QUARTER UPDATE
Earnings Release Q3 2024
2024-10-30 English
CONNECTED TRANSACTION IN RELATION TO (1) ACQUISITION OF 29.99% EQUITY INTEREST IN THE TARGET COMPANY&#x3b; AND (2) POSSIBLE VOLUNTARY PARTIAL OFFER TO ACQUIRE A MAXIMUM OF 25.01% EQUITY INTEREST IN TH
M&A Activity
2024-10-30 English
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY CHIA TAI TIANQING UNDER THE SHARE INCENTIVE SCHEME
Transaction in Own Shares
2024-10-21 English
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW INDICATION APPLICATION FOR MARKETING OF ANLOTINIB HYDROCHLORIDE CAPSULES IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF ADVANCED SOFT TISSUE SA
Regulatory Filings
2024-10-21 English
SUPPLEMENTAL ANNOUNCEMENT CONTINUING CONNECTED TRANSACTION RELATING TO THE GUARANTEE AGREEMENT
Regulatory Filings
2024-10-15 English
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY CHIA TAI TIANQING UNDER THE SHARE INCENTIVE SCHEME
Transaction in Own Shares
2024-10-09 English
VOLUNTARY ANNOUNCEMENT - SIGNING OF AN EXCLUSIVE LICENSE AND COOPERATION AGREEMENT WITH YZY BIOPHARMA
Capital/Financing Update
2024-10-08 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares
2024-10-07 English
VOLUNTARY ANNOUNCEMENT - PROGRESS UPDATE ON THE "IMPLEMENTATION OF SHARE INCENTIVE SCHEME BY CHIA TAI TIANQING"
Capital/Financing Update
2024-10-04 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares
2024-10-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
Regulatory Filings
2024-10-02 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2024
Regulatory Filings
2024-10-02 English
CONTINUING CONNECTED TRANSACTION RELATING TO THE GUARANTEE AGREEMENT
Regulatory Filings
2024-09-30 English
VOLUNTARY ANNOUNCEMENT - PHASE III STUDY RESULTS OF CULMERCICLIB IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF HR+/HER2- ADVANCED BREAST CANCER FOLLOWING ENDOCRINE TREATMENT PRESENTED AT 2024
Regulatory Filings
2024-09-27 English
NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED HOLDERS
Report Publication Announcement
2024-09-26 English
NOTIFICATION LETTER AND REPLY FORM FOR REGISTERED HOLDERS
Report Publication Announcement
2024-09-26 English
2024 INTERIM REPORT
Interim / Quarterly Report H1 2024
2024-09-26 English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF "RIVASTIGMINE TRANSDERMAL PATCH"
Regulatory Filings
2024-09-25 English
2024 INTERIM REPORT
Interim / Quarterly Report H1 2024
2024-09-23 English
VOLUNTARY ANNOUNCEMENT - PHASE III STUDY RESULTS OF ANLOTINIB HYDROCHLORIDE CAPSULES IN COMBINATION WITH PENPULIMAB INJECTION FOR FIRST-LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA WAS PRESENTE
Regulatory Filings
2024-09-16 English
VOLUNTARY ANNOUNCEMENT - PHASE III STUDY RESULTS OF ANLOTINIB HYDROCHLORIDE CAPSULES IN COMBINATION WITH BENMELSTOBART INJECTION FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA WAS PRESENTED
Regulatory Filings
2024-09-16 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
Share Issue/Capital Change
2024-09-03 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2024
Regulatory Filings
2024-09-02 English
VOLUNTARY ANNOUNCEMENT - PHASE III STUDY RESULTS OF CULMERCICLIB IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF HR+/HER2- ADVANCED BREAST CANCER FOLLOWING ENDOCRINE TREATMENT TO BE PRESENTED AT
Regulatory Filings
2024-08-29 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024
Interim / Quarterly Report H1 2024
2024-08-28 English
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III STUDY OF ANLOTINIB HYDROCHLORIDE CAPSULE IN COMBINATION WITH PENPULIMAB FOR FIRST-LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA
Regulatory Filings
2024-08-28 English
VOLUNTARY ANNOUNCEMENT - THREE RESEARCH RESULTS OF "TQC3721 (PDE3/4 INHIBITOR)" AND "TQC2731 (TSLP MONOCLONAL ANTIBODY)" WILL BE PRESENTED AT ERS 2024
Regulatory Filings
2024-08-26 English
DATE OF BOARD MEETING
Regulatory Filings
2024-08-16 English
INTERIM DIVIDEND FOR 2024
Notice of Dividend Amount
2024-08-13 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024
Interim / Quarterly Report H1 2024
2024-08-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
Regulatory Filings
2024-08-01 English
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW INDICATION APPLICATION FOR MARKETING OF BENMELSTOBART INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULE FOR FIRST-LINE TREATMENT OF ADVANCED RENA
Regulatory Filings
2024-08-01 English
NOTIFICATION OF BOARD MEETING
Regulatory Filings
2024-07-31 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2024
Regulatory Filings
2024-07-31 English
VOLUNTARY ANNOUNCEMENT - ESG PERFORMANCE RECOGNISED BY S&P GLOBAL AND FTSE RUSSELL
Environmental & Social Information
2024-07-19 English
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR CATEGORY 1 INNVOATIVE DRUG CULMERCICLIB CAPSULE "CULMERCICLIB (TQB3616)"
Regulatory Filings
2024-07-18 English
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III STUDY OF ANLOTINIB HYDROCHLORIDE CAPSULE IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA
Regulatory Filings
2024-07-16 English
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR CATEGORY 1 INNVOATIVE DRUG ROVADICITINIB TABLET "ROVADICITINIB (TQ05105)"
Regulatory Filings
2024-07-15 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
Regulatory Filings
2024-07-02 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2024
Regulatory Filings
2024-07-02 English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF "LIRAGLUTIDE INJECTION"
Regulatory Filings
2024-06-25 English
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY CHIA TAI TIANQING UNDER THE SHARE INCENTIVE SCHEME
Transaction in Own Shares
2024-06-20 English
VOLUNTARY ANNOUNCEMENT - COMPLETION OF ISSUANCE OF FIRST TRANCHE OF PANDA BONDS
Capital/Financing Update
2024-06-20 English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF CATEGORY 1 INNOVATIVE DRUG ENVONALKIB CITRATE CAPSULES "ENVONALKIB (TQ-B3139)"
Regulatory Filings
2024-06-19 English
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY CHIA TAI TIANQING UNDER THE SHARE INCENTIVE SCHEME
Transaction in Own Shares
2024-06-13 English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF "GADOTERIDOL INJECTION"
Regulatory Filings
2024-06-12 English
VOLUNTARY ANNOUNCEMENT - PUBLICATION OF STUDY FINDINGS OF PHASE II CLINICAL TRIAL OF KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)" IN THE LANCET RESPIRATORY MEDICINE
Regulatory Filings
2024-06-11 English
VOLUNTARY ANNOUNCEMENT - KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)" INCLUDED IN THE BREAKTHROUGH THERAPEUTIC DESIGNATION PROCESS
Regulatory Filings
2024-06-11 English
VOLUNTARY ANNOUNCEMENT - PRESENTATION OF POSITIVE CLINICAL DATA FROM PHASE 1 STUDY OF FS222 (CD137/PD-L1) AT THE 2024 ASCO
Regulatory Filings
2024-06-05 English
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 5 JUNE 2024
Declaration of Voting Results & Voting Rights Announcements
2024-06-05 English
ADJUSTMENT TO CONVERSION PRICE OF THE BONDS
Capital/Financing Update
2024-06-05 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information
2024-06-05 English
RETIREMENT OF EXECUTIVE DIRECTOR
Board/Management Information
2024-06-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
Regulatory Filings
2024-06-03 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2024
Regulatory Filings
2024-06-03 English
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III STUDY OF BENMELSTOBART INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA
Capital/Financing Update
2024-05-23 English
NEXT DAY DISCLOSURE RETURN
Share Issue/Capital Change
2024-05-17 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 16 MAY 2024
Declaration of Voting Results & Voting Rights Announcements
2024-05-16 English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF CATEGORY 1 INNOVATIVE DRUG BENMELSTOBART INJECTION "BENMELSTOBART (TQB2450)" IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULES FOR THE I
Regulatory Filings
2024-05-09 English
IMPLEMENTATION OF SHARE INCENTIVE SCHEME BY CHIA TAI TIANQING
Capital/Financing Update
2024-05-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
Regulatory Filings
2024-05-06 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2024
Regulatory Filings
2024-05-06 English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF CATEGORY 1 INNVOATIVE DRUG UNECRITNIB FUMARATE CAPSULES "UNECRITINIB (TQ-B3101)"
Regulatory Filings
2024-04-30 English
VOLUNTARY ANNOUNCEMENT - 52 RESEARCH RESULTS WILL BE PRESENTED AT 2024 ASCO ANNUAL MEETING
Investor Presentation
2024-04-29 English
NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS
Report Publication Announcement
2024-04-29 English
NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS
Report Publication Announcement
2024-04-29 English
FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING (OR ANY ADJOURNMENT THEREOF)
Proxy Solicitation & Information Statement
2024-04-29 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2024-04-29 English
GENERAL MANDATES TO ISSUE AND BUY BACK SHARES&#x3b; RE-ELECTION OF DIRECTORS&#x3b; AND NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2024-04-29 English
2023 ANNUAL REPORT
Annual Report FY 2023
2024-04-29 English
2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information
2024-04-29 English
VOLUNTARY ANNOUNCEMENT - CATEGORY 1 INNOVATIVE DRUG "TQA3038 (siRNA)" COMPLETED PHASE I CLINICAL STUDY
Regulatory Filings
2024-04-25 English
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement
2024-04-22 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2024-04-22 English
(1) PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES&#x3b; (2) RE-ELECTION OF DIRECTORS&#x3b; (3) PROPOSED FINAL DIVIDEND&#x3b; AND (4) NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2024-04-22 English
Environmental, Social and Governance Report 2023
Environmental & Social Information
2024-04-22 English
Annual Report 2023
Annual Report FY 2023
2024-04-22 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares
2024-04-19 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares
2024-04-19 English
VOLUNTARY ANNOUNCEMENT - CATEGORY 1 INNOVATIVE DRUG "ROVADICITINIB (TQ05105)" OBTAINED POSITIVE RESULTS IN KEY CLINICAL RESEARCH FOR REGISTRATION
Regulatory Filings
2024-04-18 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares
2024-04-17 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares
2024-04-16 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares
2024-04-15 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares
2024-04-12 English
VOLUNTARY ANNOUNCEMENT - PRESENTATION OF THE PHASE II CLINICAL STUDY DATA ON KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)"
Regulatory Filings
2024-04-11 English
VOLUNTARY ANNOUNCEMENT - DATA OF 6 STUDIES REGARDING "ANLOTINIB HYDROCHLORIDE CAPSULES", "TQB2916 (CD40 AGONIST)" AND "FHND6091 (PROTEASOME INHIBITOR)" WERE PRESENTED AT
Regulatory Filings
2024-04-10 English
CHANGE OF COMPANY LOGO
Regulatory Filings
2024-04-09 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares
2024-04-08 English
VOLUNTARY ANNOUNCEMENT - ENTER INTO STRATEGIC PARTNERSHIP WITH BOEHRINGER INGELHEIM ON INNOVATIVE ONCOLOGY PORTFOLIO IN CHINA
Capital/Financing Update
2024-04-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
Regulatory Filings
2024-04-02 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024
Share Issue/Capital Change
2024-04-02 English
FINAL DIVIDEND FOR 2023
Notice of Dividend Amount
2024-03-28 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Annual Report FY 2023
2024-03-28 English
Final Dividend for the year ended 31 December 2023
Notice of Dividend Amount
2024-03-26 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Annual Report FY 2023
2024-03-26 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information
2024-03-26 English
(1) RESIGNATION OF JOINT COMPANY SECRETARY AND CHANGE OF AUTHORISED REPRESENTATIVE AND (2) APPOINTMENT OF EXECUTIVE DIRECTOR
Board/Management Information
2024-03-26 English
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF "IOPROMIDE INJECTION"
Regulatory Filings
2024-03-24 English
VOLUNTARY ANNOUNCEMENT - UPDATE ON DEVELOPMENT PROGRESS OF MASH PRODUCTS "LANIFIBRANOR" AND "TQA2225"
Regulatory Filings
2024-03-15 English
DATE OF BOARD MEETING
Report Publication Announcement
2024-03-14 English
PROFIT WARNING
Regulatory Filings
2024-03-13 English
VOLUNTARY ANNOUNCEMENT - DATA OF PHASE II CLINICAL STUDY OF KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)" WILL BE PRESENTED AT 2024 AACR
Regulatory Filings
2024-03-13 English
VOLUNTARY ANNOUNCEMENT - DATA OF 5 STUDIES REGARDING "ANLOTINIB HYDROCHLORIDE CAPSULES" AND "TQB2916 (CD40 AGONIST)" WILL BE PRESENTED AT 2024 AACR
Regulatory Filings
2024-03-11 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
Regulatory Filings
2024-03-01 English
NOTIFICATION OF BOARD MEETING
Regulatory Filings
2024-03-01 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 2024
Regulatory Filings
2024-03-01 English
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE NEW INDICATION APPLICATION FOR MARKETING OF ANLOTINIB HYDROCHLORIDE CAPSULES AND ANTI PD-L1 "BENMELSTOBART (TQB2450 INJECTION)"
Regulatory Filings
2024-02-28 English
VOLUNTARY ANNOUNCEMENT - ANTI PD-L1 "BENMELSTOBART (TQB2450 INJECTION)" INCLUDED IN PRIORITY REVIEW AND APPROVAL PROCEDURES
Regulatory Filings
2024-02-07 English
DISCLOSEABLE TRANSACTION - DISPOSAL OF EQUITY INTEREST IN CP QINGDAO
Capital/Financing Update
2024-02-06 English
VOLUNTARY ANNOUNCEMENT - APPLICATION FOR MARKET LAUNCH OF "OBETICHOLIC ACID TABLETS" FILED AND ACCEPTED
Regulatory Filings
2024-02-01 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
Regulatory Filings
2024-02-01 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2024
Regulatory Filings
2024-02-01 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares
2024-01-26 English
NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS - NEW ARRANGEMENTS ON DISSEMINATION OF CORPORATE COMMUNICATIONS
Regulatory Filings
2024-01-26 English
VOLUNTARY ANNOUNCEMENT - PROGRESS UPDATE ON THE "SHARE PURCHASE PLAN FOR AN AGGREGATE AMOUNT OF NOT EXCEEDING HK$1 BILLION"
Transaction in Own Shares
2024-01-24 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares
2024-01-24 English
VOLUNTARY ANNOUNCEMENT - PRIORITISED EVALUATION GRANTED FOR KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)"
Regulatory Filings
2024-01-23 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares
2024-01-22 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares
2024-01-19 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares
2024-01-17 English
VOLUNTARY ANNOUNCEMENT - "ELTROMBOPAG OLAMINE TABLETS" APPROVED FOR MARKETING
Regulatory Filings
2024-01-17 English
VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE III CLINICAL STUDY OF "SEMAGLUTIDE INJECTION"
Regulatory Filings
2024-01-16 English
Letter to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
Regulatory Filings
2024-01-16 English
Letter to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
Regulatory Filings
2024-01-16 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares
2024-01-16 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares
2024-01-15 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares
2024-01-12 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares
2024-01-05 English
VOLUNTARY ANNOUNCEMENT - "EVEROLIMUS TABLETS" SUCCEEDED IN PATENT CHALLENGE AND BECAME A FIRST-TO-MARKET GENERIC DRUG
Regulatory Filings
2024-01-03 English
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME
Transaction in Own Shares
2024-01-02 English
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)"
Regulatory Filings
2024-01-02 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
Regulatory Filings
2024-01-02 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2023
Regulatory Filings
2024-01-02 English